Memantine protects against ischemia/reperfusion-induced brain endothelial permeability

Area of Science:

• Neuroscience
• Vascular Biology
• Pharmacology

Background:

• Blood-brain barrier damage and increased endothelial permeability are critical in brain ischemia and reperfusion injury.
• Memantine, used for Alzheimer's disease, has unknown effects on brain endothelial permeability.
• Investigating memantine's role in ischemia-reperfusion (I/R) injury is crucial for understanding its therapeutic potential.

Purpose of the Study:

• To investigate the effects of memantine on endothelial permeability in a human brain microvascular endothelial cell model of I/R injury.
• To elucidate the underlying mechanisms by which memantine influences brain endothelial barrier function.
• To assess memantine's potential as a therapeutic agent for stroke.

Main Methods:

• Primary human brain microvascular endothelial cells were subjected to an in vitro ischemia-reperfusion (I/R) model.
• Memantine treatment effects on inflammatory markers (TNF-α, IL-1β), tight junction proteins (occludin, VE-cadherin), matrix metalloproteinases (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase-2 (TIMP-2) were assessed.
• The role of Krueppel-like factor 2 (KFL2) and extracellular signal regulated kinase 5 (ERK5) in memantine's mechanism was investigated.

Main Results:

• Memantine prevented I/R-induced expression of tumor necrosis factor-α and interleukin-1β.
• Memantine significantly reduced endothelial monolayer permeability by increasing occludin and VE-cadherin expression.
• Memantine decreased MMP-2 activity, increased TIMP-2 expression, and elevated KFL2 via ERK5 activation.

Conclusions:

• Memantine preserves brain vascular barrier integrity during I/R injury.
• The drug modulates inflammatory responses and enhances endothelial junctional proteins.
• Memantine shows promise as a potential therapeutic agent for stroke treatment.